Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Recurrence 2Meningioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neurofibromatosis 2 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Endometrial Neoplasms 1Disease 1DLBCL 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma 1Advanced Solid Malignancies 1Advanced Metastatic Breast Cancer 1Advanced Cancer 1

Interventions

Magnetic Resonance Spectroscopy 16Hydroxyurea 7Everolimus 7Bevacizumab 7lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6Proton Therapy 6Specimen Handling 5pembrolizumab 4Surgical Procedures, Operative 4Radiosurgery 4Imatinib Mesylate 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4aldesleukin 3abemaciclib 3Tranexamic Acid 3Temozolomide 3Sunitinib 3Sodium Chloride 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Nivolumab 3Ga(III)-DOTATOC 390Y-octreotide, DOTA-Tyr(3)- 3vistusertib 2trametinib 2ribociclib 2fludarabine 2arginyllysine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Meningioma × vistusertib × Clear all
NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown
28 enrolled
CNS

Meningioma

NCT02831257 2022-06-13

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Massachusetts General Hospital

Phase 2 Completed
18 enrolled 13 charts
CNS

Meningioma, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡